Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. Millan MJ, et al. Among authors: gobert a. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. doi: 10.1124/jpet.103.051797. Epub 2003 May 15. J Pharmacol Exp Ther. 2003. PMID: 12750432
The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
Millan MJ, Gobert A, Roux S, Porsolt R, Meneses A, Carli M, Di Cara B, Jaffard R, Rivet JM, Lestage P, Mocaer E, Peglion JL, Dekeyne A. Millan MJ, et al. Among authors: gobert a. J Pharmacol Exp Ther. 2004 Oct;311(1):190-203. doi: 10.1124/jpet.104.069625. Epub 2004 May 14. J Pharmacol Exp Ther. 2004. PMID: 15146031
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ, Svenningsson P, Ashby CR Jr, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A. Millan MJ, et al. Among authors: gobert a. J Pharmacol Exp Ther. 2008 Feb;324(2):600-11. doi: 10.1124/jpet.107.132563. Epub 2007 Nov 16. J Pharmacol Exp Ther. 2008. PMID: 18024787
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, Rivet JM, Sicard D, Billiras R, Brocco M. Millan MJ, et al. Among authors: gobert a. J Pharmacol Exp Ther. 2008 Mar;324(3):1212-26. doi: 10.1124/jpet.107.134536. Epub 2007 Dec 20. J Pharmacol Exp Ther. 2008. PMID: 18096759
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
Dekeyne A, Brocco M, Loiseau F, Gobert A, Rivet JM, Di Cara B, Cremers TI, Flik G, Fone KC, Watson DJ, Papp M, Sharp T, Serres F, Cespuglio R, Olivier B, Chan JS, Lavielle G, Millan MJ. Dekeyne A, et al. Among authors: gobert a. J Pharmacol Exp Ther. 2012 Mar;340(3):765-80. doi: 10.1124/jpet.111.187534. Epub 2011 Dec 16. J Pharmacol Exp Ther. 2012. PMID: 22178753
211 results